A new pathogen emerging since November 2019, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus-2) is a virus responsible for Coronavirus disease (COVID-19) [1]. The virus has spread to the world, including Africa. It is responsible for systemic damage, including kidney damage, resulting in high mortality [2]. Indeed, this kidney involvement is associated with the occurrence of major complications independently of comorbidities and other risk factors. The mechanisms and type of kidney involvement during infection with the new coronavirus are numerous [3].

Currently, several studies showed that the mortality rate of COVID-19 patients with acute kidney injury is high, ranging from 8% to 23% [2]. One study indicated that 6.7% of patients with SARS-CoV-2 may develop impaired kidney function, and the mortality rate for those with acute kidney injury is 91.7% [4].

In Africa, several studies were conducted on kidney disease during COVID-19 [5] [6] [7]. Few studies were conducted in Côte d’Ivoire. Hence this work, whose main objective is to determine the factors associated with death in patients with acute kidney injury during COVID-19. Specifically, it involved describing the demographic, clinical, para-clinical characteristics of patients with acute kidney injury during COVID-19, describing the evolution and prognosis of patients with acute kidney injury during COVID-19, and identifying factors associated with the death of patients with acute kidney injury during COVID-19.

We report 43 cases of AKI on Covid 19 infection. In Ghana, Afriyie-Mensah and al. found 36.4% of ARF [9] in a population of 22 patients infected with covid 19 and not having pre-existing kidney injury. Ketfi found 10.7% hypercreatinemia (serum creatinine greater than 14 mg/l) in Algeria [10] in a population of 86 patients. Arrocha had reported 37.8% of AKI in a population of 82 patients in Bolivia [11]. All of these single-center studies reported less than 100 cases of AKI during COVID-19 with different methodologies.

The average age in our series was 58 years. Gupta [12] and Chan [13] in the USA reported an average age of 62 and 71 in 2 different series. Ibrahim [14] had found an average age of 65 years and Rubin [15] had found 61 years in Bordeaux (France). The age group most represented in Gupta in the United States was over 80. At Afriyie-Mensah in Ghana, 63.6% were at least 60 years old. Gutiérrez in Spain [16] found that those over 65 represented 91.8% of the population. There is a clear predominance of the elderly.

The male/female sex ratio was 4 in Bordeaux (Rubin and et al.) [15], 2 in Nigeria (Ibrahim and et al.) [14], 9.4 in India (Sampathkumar and et al.) [17], and 2.5 in the USA in Gupta’s series. Male predominance was also reported in our study. Male gender is already identified as a factor associated with the occurrence of an AKI during Covid [18] [19]. One hypothesis was the overexpression of ACE2 in male subjects [20]. Androgenic hormones would also play a role in increasing the expression of ACE2 [21].

High blood pressure was a comorbidity present in 60.4% of patients. The prevalence of hypertension was 71.7% in the USA [12], 16.7% in Nigeria [14] and 59% in India [17]. Gutierrez reported that 57.9% of his population had hypertension. The prevalence of hypertension was superimposed on ours except in the Nigerian study. There is probably an underestimation of high blood pressure cases in Nigeria where data were collected at interrogation in patients hospitalized in Intensive Care. Hypertension was identified as a risk factor for AKI during Covid [22]. Nevertheless, Hypertension is often accompanied by many factors [22].

Diabetes was a variable proportion in the studies. It was 37.2% in our series against 52.1% in Gupta in the USA [12] and Gutierrez 26.7%. It was comparable to that of Hirsch (43.3%) [23] and Chan (31%) [13]. There is strong expression of ACE2 in the kidneys of diabetic subjects [24].

Afriyie-Mensah and Arrocha found a clear predominance of respiratory distress with 90.9% and 98.7% respectively. This is superimposed on our results. The vast majority of lung damage is caused by COVID [25].

The mean hemoglobin was 10.8 g/dl and 12.3 g/dl in the Chan series [13]. Anemia was present in 53.5% of our patients compared to 16% in Ibrahim [14]. Anemia was present in 50.6% of patients in the Marques and al. series in Portugal. These results are superimposed on ours (74.4%). Anemia, common during Covid, is aggravated by the onset of kidney injury [26].

CRP levels were variable: 175 mg/L in Gupta [12] and 12.7 mg/L in Chan [13]. This is much lower than our result, related to the delay in management. CRP increases as the infection progresses [27]. It is a factor in the severity of Covid infection [28]. Inflammatory syndrome with high CRP was consistent in all our patients as in Marques (92.1%). COVID-19 is responsible for a significant inflammatory syndrome; inflammatory syndrome is also a prognostic factor.

The proportion of stage 3 patients in Arrocha in Bolivia [11] was 24.8% and 30% in Rubin [15] respectively, which is less than 58% in our series.

ATN accounted for 60.7% of patients. On renal biopsies performed, ATN lesions coexisted with several other lesions and were present in 70.6% of patients [29]. In another series, Sharma found 100% ATN lesions [30]. The predominance of ATN is related to the physio-pathology, which associates in a large proportion an effective hypovolemia, a rhabdomyolysis [31].

The majority of our patients (93%) were on antibiotics. Although no treatment showed efficacy, there is overuse of antibiotics without formal evidence of bacterial infection. This cannot be without negative effects.

Hemodialysis was initiated in 48.8% of patients. In the other series, it represented respectively 6.6% for Gupta [12], 29% for Chan [13] and 40% for Arrocha [11]. Gupta had patients with single-organ failure, with intensive care management early. On the other hand, Chan and Arrocha had a population distribution superimposed on ours. The indications of dialysis had not been specified in the series. In ours, it was dominated by anuria (46.6%).

Invasive ventilation was used in 79.1% of patients in Gupta, 68.2% of patients in Arrocha. In contrast, Afriyie-Mensah had 4.5% of patients with mechanical ventilation and Kanay had 16.4% of patients. Gupta and Arrocha had more severe patients with at least two-organ failure in intensive care. The study populations of Afriyie-Mensah and Kanay were low (28 and 22 patients respectively), which may be a selection bias. In addition, they were carried out in Africa where invasive ventilation in public hospitals is limited [32].

In Gupta, 6.6% had received therapeutic-dose anticoagulants. In contrast, we found a higher proportion of patients who received anticoagulant therapy. Coagulopathy described during COVID-19 infection motivated the use of anticoagulants. In addition, the majority of patients had high D-dimers motivating the prescription of anticoagulants before imaging to rule out venous thromboembolic disease.

The proportion of patients on vasoactive amines was 34.9%. This is superimposed on the result of Gutiérrez (46.1%) in Spain [16]. COVID-19 is responsible for a sepsis that can develop into a state of shock requiring the use of vasoactive amines [33].

Corticosteroids were used in 65.1% of patients. Afriyie-Mensah and Gutiérrez reported a percentage of corticosteroid use of 72.7% and 48.6%, respectively. The inflammation described in COVID-19 motivated the use of corticosteroids and was proposed by the WHO in severe patients [34] [35].

Death occurred in 55.8% of our patients. The percentage of deaths was 63.3% for Gupta [12], 46.4% for Hirsch [23], 50% for Chan [13] and Arrocha [11], respectively. However, it was high (90.3%) in Ibrahim [14] and low (21%) in Rubin [15]. There was a high mortality rate.

Hirsch and et al. [23] found that there was a statistically significant difference between age, male gender, race, Latino ethnicity, type of insurance, comorbidities (hypertension, diabetes), treatments used (antihypertensives, mechanical ventilation, inotropes, vasoactive amines), duration of hospitalization and KDIGO stage in univariate analysis. We did not find the same results, probably because of methodological limitations and missing data.

In our work, age over 60 years was associated with the risk of death in univariate analysis but not confirmed in multivariate analysis, probably due to the small number of our study population. Kolhe also found that age over 65 [36] was associated with a high risk of death. On the other hand, in his study, heart failure, respiratory failure and history of cancer were risk factors for death in patients with AKI during COVID-19. High age is known as a factor fragility and poor prognosis of COVID-19 [17].

Cheng found that elevated proteinuria and hematuria were factors associated with the risk of death in COVID-19 patients with AKI [1]. In Spain, systemic inflammatory response syndrome (OR = 2.4) and the occurrence of acute respiratory distress syndrome (OR = 2.8) were associated with the occurrence of death in COVID-19 patients with AKI [16].

In a study in Spain, artificial ventilation (OR = 5.9) and corticosteroid therapy (OR = 1.7) were associated with the onset of death in COVID-19 patients with AKI [16]. This was a study of 794 COVID-19 patients with AKI. We also found that invasive ventilation was associated with a high risk of death. Invasive ventilation has been identified as a death factor in COVID-19 patients [37]. Casas-Aparicio [38] in Mexico differed by KDIGO stage in symptoms such as rhinorrhea (p < 0.02), cough (p < 0.02), obesity (p = 0.04), mechanical ventilation (p = 0.01) and albuminemia (p = 0.02). Mortality was more common in KDIGO 3 (79.3%) and KDIGO 2 (68.7%) patients compared to KDIGO 1 (25%) with p = 0.004. Alfano in Italy [39] found no association between the KDIGO stage and the risk of death. In contrast, Xiao [40] in China found that the KDIGO stage was associated with the risk of dying with more deaths in stages 2 and 3 (64.3% of deaths versus 7.3% of deaths in stage 1). Blood [41] in China as well, in an ICU study, found that stage 3 was associated with the risk of death in patients with ARF during Covid (OR = 5.33 CI = 1.15 - 24.65, p < 0.01). The difference between our results and those of the literature could be explained by the lack of diuresis in our study and the small study population. It is accepted that KDIGO stage 3 is a factor of death during insufficiencies. It is recognized that stage KDIGO 3 is a factor of death during acute renal failure, regardless of cause [8].

The absence of some information in patient records related to the retrospective nature of our study influenced our comments.

Our work took place in a private institution not specialized in nephrology. Creatinine was not always dosed at intake. In addition, the diuresis data were missing. The diagnosis of COVID-19 infection was based on imaging or positive IgM serology or positive PCR. The diagnosis of kidney injury was based on evolutionary arguments. No renal biopsy was performed.

The conclusions of our study are therefore difficult to generalize, because they are based on a single center and on a small number of cases.

Mortality is high in COVID-19 patients with acute kidney injury. The factors associated with this are the advanced age of fragile patients and the severity of clinical signs justifying invasive ventilation. This raises the problem of systematic screening of patients in order to initiate early management, before the onset of respiratory distress.

What is already known on this topic: The coronavirus is responsible of kidney failure.

What this study adds: Prognosis and factor associated to death in Cote d’Ivoire.

Our thanks to the director of the Farah Polyclinic in Abidjan.

Dolaama Badomta collected data, performed data analysis and wrote the manuscript.

Konan Serge Didier and Diopoh Sery Patrick brought relevant criticism for the drafting of the research protocol, corrected the manuscript.

Moudachirou Mohamed Alex drafted the research protocol and participated in the data collection.

Tona Komlan Georges was involved in the data capture and editing of the descriptive analysis.

Amekoudi Eyram Yoan Makafui and Tsevi Mawufemo Claude reread the manuscript in order to bring relevant criticism concerning the method, the bibliographic review.

Yao Kouamé Hubert was involved in drafting the protocol, writing the results, correcting the manuscript.

The authors declare no conflict of interest.

The authorizations of the medical director of the Farah Polyclinic and the head of the Nephrology-Dialysis unit at the Farah Polyclinic have been taken. Patient anonymity was respected.

Dolaama, B., Konan, S.D., Diopoh, S.P., Moudachirou, M.A., Tona, K.G., Amekoudi, E.Y.M., Tsevi, M.C. and Yao, K.H. (2022) COVID-19 Infection and Acute Kidney Injury: About 43 Cases Report Collected at the Nephrology Department of the Farah Polyclinic in Abidjan. Open Journal of Nephrology, 12, 410-425. https://doi.org/10.4236/ojneph.2022.124042